CBIS Reports on CBS News; Historic Marijuana Vote from United States House of Representatives Creates Serious Confidence as Marijuana Wins U.S. House Vote for First Time in History

June 3, 2014

A Surprisingly Strong Majority Vote to End Federal Actions Against Medical Marijuana

COLORADO SPRINGS, Colo., June 3, 2014 /PRNewswire/ — Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development is pleased to announce a historic marijuana vote from United States House of Representatives creating serious confidence as marijuana wins U.S. House Vote for First Time in History giving a surprisingly strong majority vote to end Federal actions against medical marijuana.

Cannabis Science sees this government vote as a boost to business and investor confidence into the industry that respect the United States’ rights to medical cannabis programs around the nation.

The measure would block the federal government from interfering with states that have medical cannabis programs. The house voted 219- in favor 189 votes against. This sends an important strong message to those who are still skeptical of the progress and the future of the medical marijuana industry.

“Congress is officially pulling out of the war on medical marijuana patients and providers,” said Dan Riffle, director of federal policies for the Marijuana Policy Project.

The full article goes on to quote California GOP Rep. Dana Rohrabacher of California who submitted the amendment. California was the first state to legalize medical cannabis in 1996.

“Public opinion is shifting,” Rohrabacher said, noting a recent Pew Research Center that found 61 percent of Republicans support medical marijuana. The numbers are higher for independents and Democrats.

“Despite this overwhelming shift of public opinion, the federal government continues its hard line of oppression against medical marijuana,” concluded Rohrabacher.

Over 21 states and Washington DC have approved medical cannabis programs. Even more states have taken steps in decriminalization legislation. Colorado and Washington have full recreational programs, which means anyone over the age of 21 can purchase marijuana in those states. It is now known that more people voted for legalization in Colorado than voted for President Obama. In Denver, there are more cannabis dispensaries than Starbucks (source: CBS).

“For many years we have been discussing the course of due process in this industry. There are many steps this business must take to be fully realized and today we are seeing a big step in that due process. There are many ripple effects of all of these actions that follow into the political, economic, cultural, and social areas that will enhance over the years to come. Cannabis Science believes all of this due process will trigger an increase of business and investor confidence into this industry,” stated Robert Kane, CFO Cannabis Science.

About Cannabis Science, Inc.Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking StatementsThis Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.